Autopsy report · NCT03419130
Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer
Cause of deathOther
“Study withdrawn prior to patient enrollment”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 2
- Sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Conditions
- Infiltrating Bladder Urothelial Carcinoma; Stage II Bladder Urothelial Carcinoma AJCC v6 and v7; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
- Interventions
- Hypofractionated Radiation Therapy; Laboratory Biomarker Analysis; Pembrolizumab; Radiation Therapy
- Participants
- 0
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.